Showing 1 posts of 1 posts found.
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
PinPoint signs laboratory partnership to expand access to AI cancer risk test
NHS expands community ear and hearing pathway across 10 ICBs
London secures major investment to accelerate healthcare innovation
People with severe mental illness more likely to die early from cardiovascular disease, report finds
Yourgene wins Australian approval for chemotherapy toxicity screening assay